EICHORPublic-registry site landscape for NCT07684456, “Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer”, a Advanced Breast Cancer study sponsored by Beijing Biostar Pharmaceuticals Co., Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07684456 (registry record) |
| Study title | Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer |
| Official title | A Randomized,Controlled Phase III Study on Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast Cancer |
| Sponsor | Beijing Biostar Pharmaceuticals Co., Ltd. |
| Condition(s) | Advanced Breast Cancer |
| Phase | PHASE3 |
| Listed sites | 1 |
| Intervention(s) | Utidelone Capsule, Utidelone Injection, Capecitabine |
| Site countries | China |
At Cancer Hospital Chinese Academy of Medical Sciences — one of the facilities listed on this trial — 25 other studies are actively recruiting Advanced Breast Cancer patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Patient-friendly overview of this study: eichor.com/study/NCT07684456.
Eichor generates a preliminary site-risk snapshot for NCT07684456 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
